Sarah Cannon Research Institute | Strategic Alliance Partners

June 23, 2023

Erika P. Hamilton, MD, discusses the investigation of patritumab deruxtecan in heavily pretreated patients with metastatic estrogen receptor-positive or triple-negative breast cancer with varying levels of HER3 expression in a phase 2 trial.

June 19, 2023

Kidney and renal pelvis cancers are one of the 10 most common new malignant diagnoses in both men and women in the United States, with an estimated 52,360 new cases in men and 29,440 new cases in women per year.

June 19, 2023

Key opinion leaders share a broad perspective on relapsed/refractory diffuse large B-cell lymphoma and the current treatment landscape.

June 19, 2023

Expert panelists open their discussion on diffuse large B-cell lymphoma by reflecting on diagnostic strategies and the frontline treatment armamentarium.

June 08, 2023

Melissa L. Johnson, MD, discusses findings from the phase 2 ARC-7 trial in patients with previously untreated metastatic, PD-L1–high non–small cell lung cancer.

June 08, 2023

Melissa L. Johnson, MD, discusses findings from the phase 1 BL-B01D1-101 trial investigating the efficacy and safety of the EGFR- and HER3-directed antibody-drug conjugate BL-B01D1 in patients with locally advanced or metastatic solid tumors, including non–small cell lung cancer.

June 08, 2023

Erika P. Hamilton, MD, discusses the efficacy and safety of adjuvant abemaciclib plus endocrine therapy in patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer according to age.

June 05, 2023

Patritumab deruxtecan displayed manageable safety and produced responses in heavily pretreated patients with estrogen receptor–positive or triple-negative metastatic breast cancer with varying levels of HER3 expression, according to data from a phase 2 study presented at the 2023 ASCO Annual Meeting.

June 03, 2023

A clinically meaningful absolute risk reduction in invasive disease-free survival and distant relapse-free survival with abemaciclib plus endocrine therapy was maintained in patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer regardless of age.

April 24, 2023

The combination of darovasertib and crizotinib demonstrated clinical activity and an acceptable safety profile when utilized in first- and any-line patients with metastatic uveal melanoma.

April 21, 2023

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research, Sarah Cannon Research Institute, discusses the potential of the PI3K inhibitor RLY-2608 in PI3K-mutated breast cancer.

April 14, 2023

Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, close their discussion with clinical pearls for community oncologists treating patients with advanced RCC.

April 13, 2023

Despite a high-profile clinical disappointment, the TIGIT immune checkpoint remains an important target for anticancer therapy, with research programs testing novel agents moving forward in non–small cell lung cancer and a range of other tumor types.

April 07, 2023

In an era of genomics, proteomics, and immunology a biomarker as simple as anatomy may be useful in terms of predicting responses in patients with colorectal cancer.

April 07, 2023

Drs Barata and Garmezy give detailed thoughts on treating patients with advanced RCC who have received prior immune checkpoint inhibitors.

April 07, 2023

A comprehensive overview of the TIVO-3 trial, which compared tivozanib with sorafenib in patients with advanced renal cell carcinoma.

April 07, 2023

Robert L. Coleman, MD, FACOG, FACS, discusses a subgroup analysis of the SORAYA trial, which was presented during the 2023 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, and where the field is headed in attempt to address unmet needs for this patient population.

March 31, 2023

Experts on renal cell carcinoma discuss post-progression treatment options for RCC.

March 31, 2023

Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, outline factors taken into consideration when selecting advanced RCC treatments.

March 24, 2023

Renal cell carcinoma experts discuss clinical trials, evaluating immunotherapies and tyrosine kinase inhibitors in the front line setting of advanced RCC.